On the basis of numerous pharmacological, clinical pharmacological and clinical investigations it could be proved, that Venostasin ret., standardized on 50 mg triterpenglycosides, calculated as escine, has effects on the venous system: It has tonical effects on the veins, decreases permeability and has protective and curative properties. The mechanism of action is not fully understood, although there are some new interesting biochemical aspects regarding the attenuation of lysosomal proteoglycan destructing enzymes, which are increasingly active in patients with chronic venal insufficiency. In several double-blind randomized cross-over studies it could be demonstrated, that subjective complaints are effectively diminished. As far as objective test variables are concerned (edema), the clinical effectiveness could be shown on the basis of exact biometrical investigations. Thus the therapeutic usefulness for the treatment of chronic venal insufficiency is proven. Furthermore, regarding the good tolerability of the drug, the use of it can be recommended.